Leukemia & Proliferative Disorders of Hematic Cells Recommendations
To view Article Recommendations, you must have an active subscription.
If your access has expired, you can subscribe at $9.95 per month, the first month of your subscription will be free of charge.
If you think you should be able to access this content, please contact us.
Sign in | Subscribe | Recommend to Library
New to F1000? See this week’s top article below for a free preview of a Recommendation.
SECTION HEADS
Section Topics
- » Acute leukemia as a progression from myelodysplasia
- » Approach to acute lymphocytic leukemia
- » Approach to acute myeloid leukemia
- » Approach to childhood leukemias
- » Chronic lymphocytic leukemias: B-cell chronic lymphocytic leukemias
- » Chronic lymphocytic leukemias: hairy cell leukemia
- » Chronic lymphocytic leukemias: T and NK cell chronic leukemias
- » Hypereosinophilic syndrome
- » Leukemia biology
- » Lymphoproliferative disorders
- » Myelofibrosis
- » Myeloproliferative disorder
- » Polycythemia vera
- » Secondary erythrocytosis
LATEST RECOMMENDATION
Benjamin Schreiber, Royal Free Hampstead NHS Trust Hospital, UK. F1000 Respiratory Disorders
TOP RATED ARTICLE THIS WEEK [FREE TO VIEW]
1 Recommendation, most recent by
Benjamin Schreiber, Royal Free Hampstead NHS Trust Hospital, UK. F1000 Respiratory Disorders
- New Finding
INDIVIDUAL SUBSCRIPTIONS
Get instant access to Article Recommendations from more than 5,000 expert scientists and clinical researchers, assisted by 5,000 associates, by taking out a monthly subscription. The first month of your subscription will be free of charge.
Start your personal subscription today.
Subscribe for $9.95/monthINSTITUTIONAL SUBSCRIPTIONS
Send a recommendation to your institution's librarian or information manager to request an extended free trial for all users.
Recommend to your LibrarianIf you are a librarian or information manager, you may request an extended free trial for your academic or corporate institution.
Request an Institutional Trialyour institution might be eligible for free access via our sponsorship scheme. Check our sponsorship page.

